Pharmacological Research on Tradition Herbal Medicines By Hiroshi Watanabe (Toyama Medical and Pharmaceutical University, Toyama, Japan) and Takeshi Shibuya (Tokyo Medical University, Tokyo, Japan). Harwood Academic Publishers, Amsterdam, The Netherlands. 1999. x + 247 pp. 17 × 24.5 cm. $90.00. ISBN 90-5702-054-8.

2000 ◽  
Vol 63 (5) ◽  
pp. 736-737
Keyword(s):  
The Netherlands ◽  
Herbal Medicines ◽  
Pharmacological Research ◽  
Toyama Medical ◽  
Tokyo Medical ◽  
Medical University

scholarly journals Surgical treatment for secondary aortoesophageal fistula

2020 ◽  
Vol 15 (1) ◽  
Author(s):  
Kayo Sugiyama ◽  
Toru Iwahashi ◽  
Nobusato Koizumi ◽  
Toshiya Nishibe ◽  
Toshiki Fujiyoshi ◽  
...  
Keyword(s):  
Open Repair ◽  
Rare Condition ◽  
Aortic Aneurysms ◽  
Total Arch Replacement ◽  
University Hospital ◽  
Aortoesophageal Fistula ◽  
Thoracic Aortic Aneurysms ◽  
Life Threatening ◽  
Tokyo Medical ◽  
Medical University

Abstract Background Aortoesophageal fistula (AEF) is a relatively rare condition that is often life-threatening. Secondary AEF is a complication of previous surgery, which can be more critical and challenging than primary AEF. The number of secondary AEF is increasing due to increase in the number of thoracic endovascular aortic repair (TEVAR). Although TEVAR has become a successful alternative surgical strategy for thoracic aortic aneurysms, secondary AEF after TEVAR might be critical than other secondary AEF because of severe adhesion between the esophagus and residual thoracic aortic wall. Methods This study analyzed six patients with secondary AEF who were treated at Tokyo Medical University Hospital between 2011 and 2016. These participants included four patients who had undergone TEVAR and two who had undergone total arch replacement. Results Although they were subsequently hospitalized for a long period, open surgical repair was completed in two patients who had undergone total arch replacement. TEVAR alone was performed in two patients who had undergone TEVAR and they were discharged without major complications shortly. Combined repair of TEVAR as a bridge to open surgery was planned for two patients who had undergone TEVAR. However, reconstruction of the aorta and esophagus could not be completed in these patients due to severe adhesions, and they died during hospitalization. Conclusions Definitive open repair was successfully performed in patients with secondary AEF after total arch replacement. However, in the patients with secondary AEF after TEVAR, severe adhesion between the aorta and esophagus led to difficulty in performing a successful definitive open repair. The strategy for secondary AEF should, therefore, be decided considering the etiology of secondary AEF. In secondary AEF after TEVAR, definitive open repair is difficult to complete because of catastrophic complication, and palliative treatment using TEVAR without reconstruction of aorta and esophagus can be an alternative.

INSIDE INDUSTRY

2018 ◽  
Vol 22 (07) ◽  
pp. 46-51
Keyword(s):  
Stem Cell ◽  
Drug Discovery ◽  
3D Printing ◽  
Great Basin ◽  
Stem Cell Research ◽  
Personal Health ◽  
Standard Part ◽  
Tokyo Medical ◽  
Medical University ◽  
Oncology Center

Pharma companies are partnering AI firms to advance drug discovery. SGD110 million lab to create healthier foods and sustainable biochemicals. Philips and Singapore Institute of Advanced Medicine Holdings open regional oncology center. 3D printing will become standard part of healthcare portfolio. Vela Diagnostics buys Great Basin Scientific. APAC Biotech and Diakonos bring new immunotherapy technology to India. Kintaro Cells Power partners Tokyo Medical University to advance stem cell research. Clearbridge partners with Genome.One to offer personal health genomics programme.

Clinical Treatment to a Child with Profound Hearing Impairment-Attempt of Auditory and Cochlear Implant Center of Tokyo Medical University Hospital (ACICTMU)-

2009 ◽  
Vol 102 (6) ◽  
pp. 415-422
Author(s):  
Atsushi Kawano ◽  
Michio Hazama ◽  
Akira Hagiwara ◽  
Nobuhiro Nishiyama ◽  
Sachie Kawaguchi ◽  
...  
Keyword(s):  
Cochlear Implant ◽  
Hearing Impairment ◽  
Clinical Treatment ◽  
University Hospital ◽  
Tokyo Medical ◽  
Medical University

Photodynamic therapy using Laserphyrin for centrally located early stage lung cancer

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 7229-7229 ◽  
Author(s):  
J. Usuda ◽  
H. Kato ◽  
T. Okunaka ◽  
K. Furukawa ◽  
H. Honda ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Photodynamic Therapy ◽  
Early Stage ◽  
Stage I ◽  
University Hospital ◽  
Early Stage Lung Cancer ◽  
Endobronchial Ultrasonography ◽  
Tokyo Medical ◽  
Medical University ◽  
Stage Lung Cancer

7229 Background: In central type early stage lung cancer, the tumor must be located only as far as the segmental bronchi and be carcinoma in situ or with only limited invasion into the bronchial wall. Laserphyrin (mono-L-aspartyl chlorine e6, NPe6) is a second generation photosensitize and approved by the Japanese government and has been on sale from June 2004. Methods: Four h after the administration of Laserphyrin 40 mg/m2, we irradiated using diode laser (100 mJ/cm2). Before PDT, we evaluated the tumor lesions and tumor depth using autofluorescence bronchoscopy and endobronchial ultrasonography (EBUS), and we confirmed the area of laser irradiation. Results: From February 1980 to December 2005, a total number of 204 patients with 264 lesions of centrally located early stage lung cancer underwent photodynamic therapy (PDT) in the Department of Thoracic Surgery, Tokyo Medical University Hospital. There were 185 clinical stage 0 lesions and 79 stage I lesions. CRs and PRs were obtained in 224 lesions (84.8%) and 40 lesions (15.2%) out of 264 lesions. From July 2004 to December 2005, we performed Laserphyrin-PDT for 28 lesions of centrally located early stage lung cancer in Tokyo Medical University Hospital. The rate of CR was 92.9% (26 lesions) in 28 lesions. For Laserphyrin-PDT, Skin photosensitivity was very low and the clean-up bronchoscopies were not frequently needed, and the period of hospitalization was shorter compared to that for Photofrin-PDT. Conclusions: We conclude that PDT using Laserphyrin will be a standard option for stage 0 (TisN0M0) and stage I (T1N0M0) centrally located early stage lung cancer. No significant financial relationships to disclose.

scholarly journals Effectiveness of Photodynamic Therapy and Nd-YAG Laser Treatment for Obstructed Tracheobronchial Malignancies

1999 ◽  
Vol 5 (3) ◽  
pp. 161-166 ◽  
Author(s):  
Kinya Furukawa ◽  
Tetsuya Okunaka ◽  
Hideki Yamamoto ◽  
Takaaki Tsuchida ◽  
Jitsuo Usuda ◽  
...  
Keyword(s):  
Photodynamic Therapy ◽  
Laser Treatment ◽  
Tumor Response ◽  
Careful Consideration ◽  
Alternative Therapies ◽  
Yag Laser ◽  
Segmental Bronchus ◽  
Laser Group ◽  
Tokyo Medical ◽  
Medical University

Since 1980, advanced lung carcinomas were treated with palliative laser therapy for the purpose of opening the endobronchial stenosis and obstruction by either photodynamic therapy (PDT) or Nd-YAG laser treatment at Tokyo Medical University. A total of 258 lesions were treated, 81 by PDT and 177 by Nd-YAG laser treatment. PDT achieved effective results in 61 (75%) of 81 lesions. In the Nd-YAG laser group, 143 (81%) of 177 lesions showed effective results. When the tumor was located in the trachea or main bronchi, effective results were obtained in 73% (19 of 26) of cases treated by PDT and in 93% of cases (64 of 69) treated by Nd-YAG laser. However, in cases in which the tumor was located in lobar or segmental bronchi, the tumor response was effective in 76% (42 of 55) of PDT-treated patients and 73% (79 of 108) of Nd-YAG laser-treated patients. With a mortality rate of 0%, the greatest advantage of PDT over Nd-YAG treatment was safety. Considering complications, PDT seems to be useful for obstruction of lobar and segmental bronchus. Nevertheless, when deciding among alternative therapies, physicians treating patients with advanced lung carcinoma should give careful consideration to the benefit and complications of both laser therapies and decide the most suitable modality.

scholarly journals Comparison Between Monochorionic and Dichorionic Placentas With Special Attention to Vascular Anastomoses and Placental Share

2016 ◽  
Vol 19 (3) ◽  
pp. 191-196 ◽  
Author(s):  
Depeng Zhao ◽  
Michal Lipa ◽  
Miroslaw Wielgos ◽  
Danielle Cohen ◽  
Johanna M Middeldorp ◽  
...  
Keyword(s):  
The Netherlands ◽  
Laser Surgery ◽  
Medical Center ◽  
Interquartile Range ◽  
Medical University ◽  
Twin Pregnancies

Placental vascular anastomoses in twins lead to a shared circulation and may subsequently enable the development of severe complications such as twin–twin transfusion syndrome (TTTS) and twin anemia–polycythemia sequence (TAPS). The presence of vascular anastomoses has frequently and systematically been studied in monochorionic (MC) placentas, but only rarely in dichorionic (DC) placentas. The aim of this study was to compare the prevalence of vascular anastomoses and evaluate the sharing discordance in MC and DC placentas. All consecutive placentas of MC and DC twins delivered at the Leiden University Medical Center (the Netherlands) and Medical University of Warsaw (Poland) from 2012 to 2015 were routinely injected with colored dye and included in the study. We excluded twin pregnancies treated with fetoscopic laser surgery. A total of 258 placentas were analyzed in this study, including 134 MC placentas and 124 DC placentas. Vascular anastomoses were present in 99% (133/134) of MC placentas and 0% of DC placentas (p < .01). Placental share discordance between MC twins was significantly larger compared to DC twins, 19.8 (interquartile range [IQR] 8.1–33.3) and 10.8 (IQR 6.2–19.0), respectively (p < .01). Vascular anastomoses associated complications occurred in 16% (22/134) MC twins. Our findings show that vascular anastomoses are almost ubiquitous in MC placentas, but non-existent in DC placentas. In addition, unequal placental sharing appears to be more common in MC than in DC placentas.

Sign in / Sign up

Export Citation Format

Share Document